Posted by Michael Wonder on 04 Apr 2022
Novartis announces European Commission approval of Beovu for people living with diabetic macular oedema
31 March 2022 - Approval is based on year one data from the Phase 3 KESTREL and KITE trials investigating Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in diabetic macular oedema patients.
Novartis today announced that the European Commission has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular oedema.
